Elicio says Phase 2 AMPLIFY-7P pancreatic cancer data for ELI-002 7P earns late-breaking oral slot at ESMO 2026
Bitget2026/09/24 12:02- Elicio Therapeutics set new Phase 2 AMPLIFY-7P analyses of ELI-002 7P for an Oct. 23, 2026 oral presentation at ESMO.
- Prior results showed the trial missed its main disease-free survival goal in the overall study population.
- New pre-specified analyses aim to clarify clinical and biological activity in resected KRAS-mutant pancreatic cancer.
- Readout is expected to shape a revised Phase 3 strategy in the adjuvant setting.
- AMPLIFY-7P enrolled 144 patients across 24 U.S. sites, comparing ELI-002 7P versus observation post-standard therapy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
